Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of its drug GenSci145 tablets, which is a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Jinsai Pharmaceutical's GenSci145 tablets are classified as a Class 1 innovative chemical drug [1]. - The drug is specifically designed for patients carrying PIK3CA mutations [1]. - The approval marks a significant milestone in the development of targeted therapies for specific cancer mutations [1].

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of its drug GenSci145 tablets, which is a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Jinsai Pharmaceutical has obtained the clinical trial approval for GenSci145 tablets [1] - GenSci145 is classified as a Class 1 innovative chemical drug [1] - The drug targets patients with PIK3CA mutations in solid tumors [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Gensci Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial of GenSci145, a first-class innovative chemical drug intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1] Group 1 - The drug GenSci145 is designed to target PIK3CA mutations and has shown selective inhibitory activity against various PIK3CA hotspot mutations in preclinical studies, potentially addressing an unmet clinical need [1] - The approval marks a significant step in the drug's development, although the clinical trial process may face uncertainties [1] - The company will continue to advance its research and disclose progress in a timely manner [1]

Core Viewpoint - The recent surge in the stock price of Changchun High-tech (000661.SZ) is attributed to the announcement of a new drug, GenSci141 ointment, aimed at treating a sensitive condition in children, which has sparked investor interest reminiscent of past successes with growth hormone products [1][2][4][6][9]. Group 1: Stock Performance and Market Reaction - From January 5 to January 12, 2025, Changchun High-tech's stock experienced a price increase of 5.79% with a trading range of 9.35% [1][2]. - As of January 22, 2025, the stock price fell by 0.19% to 97.50 CNY per share, with a total market capitalization of 39.77 billion CNY [2][23]. - The stock price did not return to its initial level after the surge, indicating some sustained interest despite the subsequent decline [1][2]. Group 2: Product Details and Market Expectations - GenSci141 ointment is a topical hormone treatment for children with a specific condition related to low testosterone signaling, aiming to provide a new therapeutic option [6][28]. - The unique positioning of the drug has led to significant speculation among investors, with discussions about its potential consumer market appeal and possible expansion of its target demographic [29]. - The condition targeted by GenSci141 is rare, with an incidence rate of approximately 0.0015% in the U.S. and 0.14% reported in Zhengzhou, China [29]. Group 3: Historical Context and Business Strategy - Changchun High-tech previously achieved significant success with growth hormone products, establishing a near-monopoly and reaching a market capitalization of over 210 billion CNY [10][32]. - The company has faced challenges since 2022 due to price reductions from centralized procurement and increased competition, leading to a decline in revenue and profit margins [10][34]. - The management has shifted focus towards innovative drug development, with expectations of surpassing 1 billion CNY in revenue from new products by 2025 [36][15]. Group 4: Financial Performance and Challenges - In 2024, the company reported its first negative revenue growth in nearly two decades, with a 43.01% year-over-year decline in net profit [10][34]. - For the first three quarters of 2025, net profit decreased by 58.23%, with a significant drop of 82.98% in the third quarter alone [10][34]. - The company has increased its R&D spending to support its innovation pipeline, with a 17.32% year-over-year increase in R&D investment [15][36]. Group 5: Future Prospects and Risks - The success of GenSci141 and other innovative products is critical for the company to overcome the decline in its core growth hormone business [17][40]. - The company is exploring a listing on the Hong Kong stock exchange to alleviate cash flow pressures and support international expansion [40]. - There are concerns regarding the sustainability of its business model and the potential for regulatory challenges in the current healthcare environment [41].

Core Insights - The article highlights the participation of Gensci Pharmaceutical at the 44th JPMorgan Healthcare Conference, showcasing its innovative drug development and research capabilities, which attracted significant investor interest [1][2]. Group 1: Innovative Drug Pipeline - Gensci Pharmaceutical presented seven innovative drug pipelines targeting major disease areas such as oncology, respiratory, immunology, endocrinology, and women's health, with potential First-in-Class (FIC) or Best-in-Class (BIC) profiles [2][3]. - The company emphasized its advanced technology platforms, including long-acting release, conjugation technology, targeted delivery, and AI-assisted drug design, which are crucial for developing competitive drug candidates [2][3]. Group 2: Clinical Development Highlights - Gensci's GenSci134, a long-acting growth hormone analog, is in Phase I clinical trials, aimed at improving patient compliance in growth hormone deficiency [3]. - The NK3R antagonist GenSci074 for menopausal vasomotor symptoms has met all primary endpoints in Phase II trials, showing significant improvement over placebo, with plans for a global Phase III trial in Q2 2026 [3]. - The PD-1 agonist GenSci120 has received clinical approval in China and the U.S., demonstrating potential for chronic immune inflammatory diseases [4]. Group 3: Oncology Advancements - Gensci's GenSci128, targeting TP53 Y220C mutations, has entered clinical trials, addressing a significant unmet need in solid tumors [5]. - The new PI3Kα inhibitor GenSci145, recently accepted for IND, shows selective inhibition of PIK3CA mutations and potential for treating advanced solid tumors with brain metastases [5]. Group 4: Strategic Development and Global Expansion - Gensci is advancing over 40 clinical research projects and has achieved a milestone with the overseas licensing of GenSci098, totaling $1.365 billion, marking international recognition of its innovation [9]. - The company aims to develop a robust pipeline through a strategy that combines growth hormone, innovative drugs, and overseas business development, positioning itself for high-quality growth [9]. - The JPM conference serves as a platform for Gensci to showcase its innovations and foster global partnerships, reflecting a shift in the industry towards quality and global outreach [9].

Core Viewpoint - The company has signed an exclusive licensing agreement for the GenSci098 injection project with Yarrow Bioscience, which includes a $70 million upfront payment to support its cash reserves and future development plans [2][3]. Group 1: Licensing Agreement Details - The exclusive licensing agreement was approved by the company's board on December 15, 2025, allowing Yarrow to develop, produce, and commercialize GenSci098 outside Greater China [3]. - The first payment of $70 million was received by the company on January 14, 2026, which will enhance the company's cash reserves and support its international strategy [3]. Group 2: GenSci098 Injection Project - GenSci098 is a humanized monoclonal antibody designed to treat thyroid-related conditions, specifically targeting TSHR to inhibit thyroid hormone synthesis and release [4]. - Clinical trials for GenSci098 have been approved in both mainland China and the United States for thyroid eye disease (TED) and Graves' disease (GD), indicating its potential as a new treatment option [4].

Core Viewpoint - Changchun High-tech has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project, receiving an initial payment of $70 million, which enhances the company's cash reserves and supports its future R&D and internationalization strategy [1][4]. Group 1: Licensing Agreement Details - The agreement allows Yarrow to have global exclusive rights for the development, production, and commercialization of GenSci098 injection outside Greater China, specifically targeting thyroid-related eye disease (TED) and Graves' disease (GD) [3]. - Changchun High-tech's subsidiary, SaiZeng Medical, retains the rights for development and commercialization of GenSci098 in China [3]. Group 2: Product Information - GenSci098 is a humanized monoclonal antibody designed to treat hyperthyroidism by blocking the synthesis and release of thyroid hormones and preventing the proliferation of thyroid cells [2]. - The injection has shown potential in preclinical data and ongoing Phase I clinical trials for TED, with plans for further clinical development targeting GD [2]. Group 3: Financial Implications - SaiZeng Medical is expected to receive a total of $120 million in upfront and milestone payments, including the initial $70 million and an additional $50 million for recent development milestones [4]. - The agreement also includes potential milestone payments of up to $1.365 billion and over 10% sales royalties post-product launch [4].

Core Viewpoint - Changchun Gaoxin has received a $70 million upfront payment from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, enhancing the company's cash reserves and supporting its future R&D and international strategy [1] Group 1 - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology, which entered into an exclusive licensing agreement with Yarrow Bioscience for the GenSci098 injection project [1] - The agreement grants Yarrow exclusive rights to develop, produce, and commercialize GenSci098 injection globally, excluding Greater China [1] - The payment received will further strengthen the company's cash reserves and assist in advancing its pipeline development and international strategy [1]

Core Viewpoint - Changchun High-tech (000661) has made progress in the GenSci098 injection project by signing an exclusive licensing agreement, receiving an initial payment of $70 million from Yarrow [1] Group 1: Company Developments - The company's subsidiary, Jinsai Pharmaceutical, through its wholly-owned subsidiary, Saizeng Medical, has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project [1] - GenSci098 injection is a humanized TSH receptor antagonist monoclonal antibody developed by Jinsai Pharmaceutical, classified as a first-class new drug for therapeutic biological products [1]

证券代码：000661 证券简称：长春高新 公告编号：2026-003 长春高新技术产业（集团）股份有限公司 关于 GenSci098 注射液项目签署独家许可协议的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 二、有关 GenSci098 注射液项目 1 GenSci098 注射液是金赛药业自主研发的一种人源化促甲状腺激素受体 （TSHR）拮抗型单克隆抗体，为治疗用生物制品 1 类新药。通过特异性与甲状 腺或球后组织内 TSHR 结合，阻断其与自身抗体结合，进而抑制甲状腺激素的合 成和释放、抑制甲状腺细胞的增殖、阻止 HA 和炎症因子释放，从而发挥改善甲 亢的作用，并同时具有改善突眼的作用。本品临床前数据、在研的甲状腺眼病 （TED）的 I 期临床研究以及同靶点其他药物的临床数据表明，GenSci098 有潜 力作为一种治疗弥漫性毒性甲状腺肿的新型治疗手段，相关临床试验可以推动后 续该产品针对弥漫性毒性甲状腺肿人群的临床开发。 目前，GenSci098 注射液已于 2024 年 8 月同步在中国大陆及美国获批开展 用于甲状腺相关眼病（T ...